NEW

Health Care Leaders Form Trustworthy & Responsible AI Network (TRAIN)

Monday, at the HIMSS 2024 Global Health Conference, a new consortium of healthcare leaders announced the creation of the Trustworthy & Responsible AI Network (TRAIN), which aims to operationalize responsible AI principles to improve the quality, safety and...

EPA Rule to Slash EtO Emissions, Reduce Cancer Risk

The U.S. Environmental Protection Agency has announced a rule that will reduce lifetime cancer risks for people living near commercial sterilization facilities across the country. The final amendments to the air toxics standards for ethylene oxide commercial...

AI Revolutionizes General Surgery, says GlobalData

Artificial intelligence (AI) integration in general surgery has surged, promising revolutionary advancements in precision and patient outcomes. AI tools have transformed preoperative planning, intraoperative assistance, and postoperative care, enhancing diagnostic...

Study Shows Potential for Using AI Tools to Detect Healthcare-Associated Infections

A new proof-of-concept study published today in the American Journal of Infection Control (AJIC) reports that artificial intelligence (AI) technologies can accurately identify cases of healthcare-associated infections (HAI) even in complex clinical scenarios. The...

New FDA Actions to Promote the Safe Use of Surgical Staplers and Staples for Internal Use: Proposed Reclassification, Draft Guidance, and Public Panel Meeting

The U.S. Food and Drug Administration (FDA) is concerned by the large number of adverse events associated with surgical staplers and staples specifically for internal use. We are taking multiple actions to help promote patient safety and reduce the risk of adverse events associated with these devices.

Between January 1, 2011 and March 31, 2018, the FDA received over 41,000 medical device reports related to surgical staplers and staples for internal use, including 366 reported deaths, over 9,000 serious injuries, and over 32,000 malfunctions.

As first announced in our March 8, 2019, letter to healthcare providers, the FDA has now issued:

  • A draft guidance, “Surgical Staplers and Staples for Internal Use – Labeling Recommendations,” to help manufacturers develop labeling with information about specific risks, limitations, and directions for use of the device, which is open for public comment through June 24, 2019.
  • A proposed order to reclassify surgical staplers for internal use from Class I to Class II medical devices, which is open for public comment through June 24, 2019.
  • Currently, surgical staplers for internal use are regulated as Class I medical devices, which do not require a premarket submission to the FDA.
  • Classification as a Class II device would allow the FDA to establish mandatory special controls and require premarket notification (510(k)).
  • A Federal Register notice formally announcing an open public meeting of the General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee. On May 30, 2019, the committee will discuss and make recommendations regarding the proposed reclassification of surgical stapler devices for internal use from Class I (general controls) to Class II (special controls).

We invite any interested parties to participate in the public panel meeting, either by attending the meeting, presenting at the meeting, or submitting written comments.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X